| Full Name | Sara C Burnside |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 389 Adams St, Afton, Wyoming |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023468634 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | PCSW-673 (Wyoming) | Primary |
| Entity Name | North Lincoln County Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730132523 PECOS PAC ID: 4789580218 Enrollment ID: O20031208000415 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.
Today President Barack Obama signed into law The Patient Protection and Affordable Care Act (H.R.3590). As an association representing behavioral healthcare professionals and organizations, we are committed to improving the lives of people of all ages experiencing psychiatric and substance use disorders. This historic legislation offers hope and help in a number of ways.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI's IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area.
› Verified 6 days ago
| Entity Name | North Lincoln County Hospital District |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1255376406 PECOS PAC ID: 4789580218 Enrollment ID: O20101103000284 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.
Today President Barack Obama signed into law The Patient Protection and Affordable Care Act (H.R.3590). As an association representing behavioral healthcare professionals and organizations, we are committed to improving the lives of people of all ages experiencing psychiatric and substance use disorders. This historic legislation offers hope and help in a number of ways.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI's IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area.
› Verified 6 days ago
| Entity Name | High Country Behavioral Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457472748 PECOS PAC ID: 0648454587 Enrollment ID: O20110418000512 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.
Today President Barack Obama signed into law The Patient Protection and Affordable Care Act (H.R.3590). As an association representing behavioral healthcare professionals and organizations, we are committed to improving the lives of people of all ages experiencing psychiatric and substance use disorders. This historic legislation offers hope and help in a number of ways.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI's IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sara C Burnside, PCSW 901 Adams St, Afton, WY 83110-9621 Ph: (307) 885-9883 | Sara C Burnside, PCSW 389 Adams St, Afton, WY 83110 Ph: (307) 885-9883 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.
Today President Barack Obama signed into law The Patient Protection and Affordable Care Act (H.R.3590). As an association representing behavioral healthcare professionals and organizations, we are committed to improving the lives of people of all ages experiencing psychiatric and substance use disorders. This historic legislation offers hope and help in a number of ways.
GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI's IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area.
› Verified 6 days ago
Reed Lesuma, PCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 389 Adams St., Afton, WY 83110 Phone: 307-885-9883 Fax: 307-885-5206 | |
Lorry Stufflebeam, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 70 3rd Ave, Afton, WY 83110 Phone: 307-522-1541 Fax: 307-459-6800 | |
Ms. Mary A Mccarthy, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 422 S Washington St, Ste 3, Afton, WY 83110 Phone: 907-545-6645 | |
Barbara Merritt, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 389 Adams St, Afton, WY 83110 Phone: 307-885-9883 Fax: 307-885-5206 |